​​​​​​​Aurobindo receives FDA OK for Lyrica

Aurobindo has obtained the Food and Drug Administration's blessing for pregabalin capsules in dosage strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg.

Aurobindo's pregabalin capsules, which are the generic of Upjohn's Lyrica, are indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, management of postherpetic neuralgia, adjunctive therapy for adult patients with partial onset seizures, management of fibromyalgia and management of neuropathic pain associated with spinal cord injury.  

[Read more: Aurobindo gets FDA nod for 3 generics]

Pregabalin capsules have a market value of roughly $238 million for the 12 months ending January 2023, according to IQVIA.

[Read more: Aurobindo, Cipla, Vitaris to manufacture HIV PrEP generics]